撰文丨王聪 编辑丨王多鱼 排版丨水成文 激素受体阳性 （HR + ） 乳腺癌，包括 雌激素受体阳性 （ER + ） 和孕激素受体阳性 （PR + ） 乳腺癌， 占所有乳腺癌诊断病例的 75%， 内分泌疗法 是 HR + 乳腺癌患者在辅助治疗和转移性治疗中的主要治疗手 段。然而，标准内分泌疗法的疗效因原发性或获得性耐药而受到限制。 周期性 禁食 可增强内分泌疗法对 HR + 乳腺癌的疗效，并在动物模型中延缓获得性治疗耐药性。临床研究 表明，只喝水的 禁食或模拟禁食饮食 （FMD；低热量、低蛋白、低糖的素食饮食，能重现禁食的代谢效 应） 对于患有不同类型的癌症患者 （ 乳腺癌、黑色素瘤、结直肠癌、肺癌及妇科肿瘤 ） 来说是可行且安 全的。 之前的研究显示 ， 禁食可增强内分泌疗法对 HR + 乳腺癌的治疗效果 。然而，这种益处背后的 这种效应 背后的机制仍不清楚。 此外，辅助内分泌治疗方案需要连续每天治疗五到十年，这使得在内分泌治疗期间 长期坚持联合饮食干预极具挑战性。 2025 年 12 月 10 日， 荷兰癌症研究所、意大利热那亚大学的研究人员在国际顶尖学术期刊 Nature 上发 表了题为： Fasting ...

Core Viewpoint - Breast cancer has become the most prevalent malignant tumor globally, and its prevention and treatment are crucial for public health. The "2025 Breast Cancer Precision Diagnosis and Long-term Survival Value Seminar" held in Shanghai focused on optimizing breast cancer diagnosis and treatment under the context of precision medicine, emphasizing patient-centered long-term survival strategies [1]. Group 1: Conference Overview - The seminar was chaired by prominent figures in the field, including Professor Shen Zhenzhou and Academician Xu Binghe, gathering top scholars to discuss the enduring value of classic treatment protocols and long-term patient management [1][3]. - The event highlighted the evolution of treatment philosophies, transitioning from "maximum tolerated" to "minimum effective" approaches, underscoring the importance of established treatment protocols as foundational elements in breast cancer care [3][5]. Group 2: Clinical Insights - Professors Shao Zhimin and Zhang Jin emphasized the clinical significance of classic drugs, advocating for deep academic exchanges to solidify consensus on their value while accelerating the development of innovative therapies [5][6]. - The discussion included the need for a dual focus on innovation and the enduring efficacy of classic treatments in enhancing patient survival and quality of life [6]. Group 3: Industry Perspectives - Dong Hao, Deputy General Manager of China Resources Pharmaceutical Group, articulated the company's commitment to integrating classic treatment strategies into clinical practice to meet unmet patient needs [8]. - The seminar also addressed the challenges and opportunities within the Chinese pharmaceutical industry, particularly in the context of drug approval reforms and the need for efficient commercialization strategies [10]. Group 4: Quality Control and Standardization - The establishment of quality control alliances and standardized treatment protocols was discussed, with a focus on enhancing regional healthcare delivery and ensuring equitable access to breast cancer care [11]. Group 5: Future Directions - The seminar concluded with a focus on the future of breast cancer treatment, emphasizing the importance of classic drugs alongside innovative therapies, particularly in the context of ongoing clinical trials and research [35][38]. - The "Net Benefit Long-term Survival Navigation Plan" was launched, aiming to improve overall management of breast cancer through collaborative efforts [31].

Core Viewpoint - The study highlights the significance of gene fusions, particularly ADK fusions, in hormone receptor-positive breast cancer, suggesting they are key drivers of cancer progression and potential therapeutic targets [2][3][5]. Group 1: Gene Fusion Insights - The research presents a comprehensive landscape of gene fusions in hormone receptor-positive (HR+) breast cancer, identifying ADK fusions, such as KAT6B::ADK, as novel and recurrent driver genes [3][5]. - The KAT6B::ADK fusion gene enhances the metastatic potential of breast cancer and confers resistance to tamoxifen, a common anti-estrogen drug used in breast cancer treatment [7]. Group 2: Mechanisms and Therapeutic Implications - Mechanistically, KAT6B::ADK activates ADK kinase activity through liquid-liquid phase separation (LLPS), triggering the activation of integrated stress response signaling pathways [7]. - Organoids derived from HR+/HER2- breast cancer patients carrying KAT6B::ADK exhibit higher sensitivity to ADK inhibitors, underscoring the therapeutic potential of this fusion gene in breast cancer treatment [9].

研究报告 2025/06 www.leadleo.com 2025年 中国乳腺增生用药行业概览：当"她未言说" 的疼痛被听见，中国女性健康市场是否已 按下"加速键"？ 2025 China Breast Hyperplasia Medication Industry 2025年中国バストアップ薬産業 报告标签：乳腺科、乳腺增生症 主笔人：钟琪 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性 文件（在报告中另行标明出处者除外）。 ，任何人不得以任何方式擅自 复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院 "或"头豹"的商号、商标，头豹研究院无任何前述名称之外的其他分支机构，也未授权或聘用其他任何 第三方代表头豹研究院开展商业活动。 研究报告 | 2025/06 中国乳腺增生用药行业 西药方面，治疗乳腺增生症的药物有他莫昔芬 与溴隐亭。他莫昔芬有竞争性抑制体内雌激素 作用，对乳房疼痛有较好的缓解作用，也可改 善中成药起效慢的弊端。中药方面， ...